Open radical nephroureterectomy (ORN) with excision of the distal ureter and bladder cuff is considered the current standard of care for the treatment of nonmetastatic upper tract urothelial carcinoma (UTUC) [1] . However, ORN has been associated with significant morbidity. Laparoscopy has been shown to be equally effective as open surgery for some urologic malignancies while resulting in less perioperative morbidity [2] . In 1991, Clayman et al first described the technique of laparoscopic nephroureterectomy (LRN), and since then it has emerged as an accepted minimally invasive treatment alternative to ORN. However, the oncologic efficacy of LRN and its equivalence to ORN have not been established.
UTUC is a biologically aggressive malignancy with a high potential for disease recurrence and eventual death. Some investigators have hypothesized that tumor dissection and high-pressure pneumoperitoneum during LRN are associated with a higher risk of bladder and/or local recurrence as well as port-site metastasis [3] . The differential effect of LRN versus ORN on oncologic outcomes after radical nephroureterectomy (RN) remains controversial. Although several recent studies suggested comparable oncologic results between ORN and LRN in well-selected patients [4] [5] [6] [7] [8] [9] [10] , others reported a higher risk of intravesical disease recurrence with LRN as compared with ORN [11] [12] [13] .
We hypothesized that there is no difference in clinical outcomes between ORN and LRN when performed by expert surgeons. To test this hypothesis, we studied the effect of surgical approach on bladder-only recurrence, any recurrence, and disease-specific survival at a single cancer center with genitourinary surgeons and pathologists.
2.
Materials and methods 
Patient selection and technique

2.3.
Follow-up regimen Disease recurrence was defined as any documented recurrence-by radiograph, endoscope, or pathology-in the bladder, contralateral kidney, operative site, regional lymph nodes, or distant metastases.
Cause of death was determined by chart review corroborated by death certificate. Most patients who were identified as having died of UTUC had progressive widely disseminated metastases at the time of death. recurrence, where patients without bladder recurrence were censored at their date of last follow-up. The probability of disease-specific death was estimated using the cumulative incidence function, accounting for the competing risk of death from other causes. All covariates adjusted for in
Statistical methods
the multivariable models were prespecified before any data analysis. All reported p values are two sided, and statistical significance was set at <0.05. Statistical analyses were conducted using Stata v.11.0 (StataCorp, College Station, TX, USA).
Results
In the cohort of 274 patients who underwent RN without prior or concurrent radical cystectomy, 95 (35%) had primary non-muscle-invasive bladder cancer (NMIBC; Table 1 ). Those with primary bladder cancer were more likely than patients with primary UTUC to have an ASA class of !3 (57% vs 42%); there were no other differences between the two groups.
In comparison with the historical ORN cohort, the contemporary ORN cohort was more likely to have a lymph node dissection (81% vs 50%) and shorter operative times (median: 164 vs 225 min), but a similar blood loss and a higher rate of transfusion (26% vs 16%); median length of hospital stay decreased from 7 to 5 d.
Comparisons between ORN and LRN focused on the contemporary group of patients who underwent surgery between 2002 and 2008: 109 (67%) had ORN and 53 (33%) had LRN (Table 2) . Patients in the LRN group were slightly older (median: 73 vs 71 yr of age) and were also more likely to have an ASA class of !3 (58% vs 48%); however, these differences were not statistically significant (both p ! 0.4). Pathologic outcomes were also similar between the surgical approaches. Although a lymph node dissection was performed less often in LRN patients (70% vs 81%), there was no significant difference in the number of nodes evaluated ( p = 0.9). A median of eight nodes was evaluated for each group (interquartile range: 4-15 for both groups; range: 1-39 for open and 1-46 for laparoscopic). We observed significant differences in blood loss, operative time, and 18 (10) 13 (14) Pathologic CIS, n (%) 44 ( (Table 3) . The median follow-up for patients without recurrence was 23 mo. Overall, 99 of 162 patients experienced disease recurrence of any type: 70 in the ORN group and 29 in the LRN group. The most common type of disease recurrence was within the bladder (51 ORN patients and 15 LRN patients). Fig. 1 shows the probability of freedom from recurrence following RN, stratified by surgical approach. The recurrence-free probabilities were similar between groups ( p = 0.9 by log-rank test). The 2-yr probability of freedom from any recurrence was 38% (95% CI, 28-47%) for the ORN and 42% (95% CI, 27-56%) for the LRN group. Fig. 2 shows the probability of freedom from recurrence following RN, stratified by pathologic stage; the recurrence-free probabilities were similar between the groups regardless of pathologic stage. On multivariable analysis, surgical approach was not significantly associated with any recurrence (adjusted hazard ratio [HR]: 0.88 for laparoscopic vs open; 95% CI, 0.57-1.38; p = 0.6) or bladderonly recurrence (adjusted HR: 0.78; 95% CI, 0.46-1.34; p = 0.4; Table 4 ). The 2-yr probability of freedom from bladder recurrence was 50% (95% CI, 40-60%) for the ORN group and 61% (95% CI, 45-74%) for the LRN group. Exclusion of patients with previous NMIBC did not change the statistical or clinical significance of the findings; the proportion of patients with previous NMIBC was the same for both groups (36%).
In the ORN group, there were 26 deaths from UTUC and 10 deaths from other causes. In the LRN group, there were nine deaths from UTUC and six deaths from other causes. Fig. 3 shows the cumulative incidence of disease-specific death, stratified by surgical approach; the cumulative incidence of disease-specific death was similar between groups ( p = 0.9). The 2-yr cumulative incidence of diseasespecific death was 14% (95% CI, 9-22%) for the ORN group and 18% (95% CI, 8-31%) for the LRN group.
Discussion
Some investigators have suggested that tumor manipulation during LRN may lead to increased gravitational migration of tumor cells and eventual implantation in the bladder. In addition, the high-pressure environment required for the laparoscopic procedure could allow tumor cells to spread through pressurized aerosolization [3] . It is known that the development of secondary bladder cancer after primary UTUC can occur in up to 50% of the patients, mainly due to tumor cells seeding [15] . Furthermore, portsite tumor cell implantation has also been reported as a possible concern with LRN [16] . However, these potential risks of LRN are controversial and need testing. In accordance with many previous studies, we found no statistically significant difference in any recurrence, bladder-only recurrence, and disease-specific death between patients treated with ORN and those with LRN [4] [5] [6] [7] [8] [9] [10] . In a single-center study with 140 patients, Greco et al did not find any difference in recurrence rates between ORN and LRN [4] . Also in a single-center study with 102 patients, Waldert et al were unable to show any difference in recurrence rates between groups [6] . Interestingly, in a Fig. 1 -Kaplan-Meier estimates of recurrence-free probabilities following nephroureterectomy, stratified by surgical approach.
multicenter study with 1003 patients, Kamihira et al reported that hand-assisted retroperitoneal LRN was an independent risk factor for bladder-only recurrence compared with pure LRN [11] . All cases in our study were pure LRN; therefore we could not address this issue. In a large single-center series analyzing 385 RNs, Huang et al found that LRN had a significantly greater risk of bladder-only recurrence in the univariate analysis; however, multivariable analysis failed to characterize treatment modality as an independent risk factor for recurrence [12] . The only randomized prospective study comparing LRN and ORN did not find any differences concerning bladder-only recurrence. However, the study's conclusions were limited by the small number of patients in each arm and one single surgeon performing both techniques [17] . In agreement with previous retrospective studies [6, 8, 9 ], we did not find any significant association between surgical approach and disease-specific death. Our 2-yr cumulative incidence of disease-specific death was 14% for the open group and 18% for the laparoscopic group. In a single-center series of 224 patients, Manabe et al did not find any significant difference in disease-specific survival or overall survival between ORN and LRN [9] . In a multiinstitutional study with 1249 patients, Capitanio et al found a difference in the univariate analysis favoring LRN; however, this was explained by a selection bias with regard to tumor size, stage, and other features favoring LRN patients. After adjustment for the effect of tumor stage, no significant difference was found between ORN and LRN [8] . Similarly, in a single-center series of 240 patients, Terakawa et al found a slightly lower disease-specific survival rate in LRN patients with high-grade disease; however, surgical procedure was not an independent prognostic factor in multivariable analysis [18] . Whereas the single-center studies were limited by small sample size, the multicenter studies lacked centralized pathologic evaluation and heterogeneity in disease severity and treatment. Moreover, many studies spanned !20 yr, with changes in disease management. In the only prospective randomized study published in the literature, the authors found lower rates of metastasis-free survival and cancerspecific survival in patients treated with LRN, after adjusting for pT3 category and high-grade disease; for organ-confined disease, there was no difference between groups [17] . The authors labeled their results preliminary because of the small number of patients.
The present study has several limitations, including its retrospective nature. We included patients with previous NMIBC, which is a known risk factor for bladder recurrence; however, we identified exactly the same proportion of patients with previous bladder tumor in both groups. Nevertheless, the small numbers of LRN patients and the short follow-up limit generalizations of our findings. Despite these limitations our study has some strengths, such as centralized pathologic review and standardized follow-up. Moreover, clinical and pathologic characteristics were similar between the LRN and ORN groups, avoiding the selection bias commonly seen with the introduction of new surgical techniques. Ninety-two percent of patients had bladder cuff control done by the open technique. The homogeneity of this approach avoids confounding when analyzing bladder recurrence rates. Most of our patients had undergone lymphadenectomy, which is not commonly seen in other series of LRN. 
Conclusions
Based on our retrospective analysis of trained genitourinary oncologic surgeons, no evidence indicates that oncologic control is compromised for patients treated with LRN in comparison with ORN. Despite a well-controlled design, our study lacks a sufficient number of patients treated with LRN as well as a longer follow-up. Well-controlled multi-institutional randomized trials are needed to validate LRN as an oncologically efficacious procedure for patients with UTUC.
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